Emerging Life Science and Biotech Companies Find Critical Success at Mass Innovation Labs
Vertex Provides Update on Business and Financial Performance and Research and Development Programs
Domestic stocks have proved resilient in a tumultuous 2016.
Regenerative Medicine Market: 2016-2021 - Focus on Orthopedic & Musculoskeletal Spine, Dermatology, Cardiovascular, Central Nervous System, Oncology & Diabetes - Research and Markets
Options on this firm's blockbuster cost a little but pay off big.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
We dive into the process for adding companies and booting them from the iconic index.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.